Federal Register / Vol. 83, No. 147 / Tuesday, July 31, 2018 / Notices 36941 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Committee on Vital and Health 

Statistics: Meeting 

Pursuant to the Federal Advisory 

Committee Act, the Department of 

Health and Human Services (HHS) 

announces the following advisory 

committee meeting. 

Name: National Committee on Vital 

and Health Statistics (NCVHS), Full 

Committee Meeting. 

Date and Times: Thursday, September 

13, 2018: 9:00 a.m.–5:00 p.m. (EDT); 

Friday, September 14, 2018: 8:30 a.m.– 

3:00 p.m. (EDT). 

Place: Melrose Georgetown Hotel, 

2430 Pennsylvania Avenue NW, 

Washington, DC 20037. 

Status: Open. 

Purpose: At the September 13–14, 

2018 meeting, the Committee will hear 

presentations, hold discussions on 

several health data policy topics and 

continue work on projects outlined in 

the NCVHS 2018 workplan. Anticipated 

action items during this meeting include 

an Environmental Scan Report on 

Health Terminologies and Vocabularies 

(T/V); and a summary report of the 

health T/V expert roundtable meeting 

held July 17–18, 2018. The NCVHS 

Population Health Subcommittee will 

hold a session with panelists to provide 

input to the Committee regarding 

strategies and resources/tools to 

increase access to small area data, and 

in general, the challenges in making 

relevant sub-national level health data 

more readily available. Subcommittee 

activities for discussion include the 

Predictability Roadmap as part of the 

Standards Subcommittee’s project to 

identify possible approaches to improve 

predictability and improvements in the 

adoption and processes related to 

updating standards and operating rules 

for electronic administrative 

transactions (e.g., claims, eligibility, 

electronic funds transfer). The Privacy, 

Confidentiality & Security 

Subcommittee will continue its focus on 

use cases that highlight the intersection 

of the regulated and unregulated 

domains for its ‘‘Health Information 

Privacy and Security Beyond HIPAA’’ 

project, and will propose a model that 

depicts the opportunities to address 

risks to individually identifiable 

information through improved 

stewardship for consideration by the 

full Committee. 

The Committee will initiate 

discussion regarding plans for the 

NCVHS Thirteenth Report to Congress. 

The agenda times and topics are subject 

to change. There will be a public 

comment period on both meeting days. 

Please refer to the posted agenda for any 

updates. 

Contact Persons for More Information: 

Substantive program information may 

be obtained from Rebecca Hines, MHS, 

Executive Secretary, NCVHS, National 

Center for Health Statistics, Centers for 

Disease Control and Prevention, 3311 

Toledo Road, Hyattsville, Maryland 

20782, telephone (301) 458–4715. 

Summaries of meetings and a roster of 

Committee members are available on the 

home page of the NCVHS website: 

www.ncvhs.hhs.gov, where further 

information including an agenda and 

instructions to access the audio 

broadcast of the meetings will be 

posted. 

Should you require reasonable 

accommodation, please contact the CDC 

Office of Equal Employment 

Opportunity on (770) 488–3210 as soon 

as possible. 

Dated: July 25, 2018. 

Laina Bush, 

Deputy Assistant Secretary for Planning and 

Evaluation, Office of the Assistant Secretary 

for Planning and Evaluation. 

[FR Doc. 2018–16361 Filed 7–30–18; 8:45 am] 

BILLING CODE 4151–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Emergency Use of Treatment for 

Uncontrolled Hemorrhage Due to 

Agents of Military Combat; Correction 

AGENCY: Office of the Secretary, 

Department of Health and Human 

Services. 

ACTION: Notice, correction. 

SUMMARY: The Department of Health and 

Human Services is correcting a notice 

that appeared in the Federal Register on 

July 16, 2018. The notice announced the 

Secretary’s Declaration Regarding 

Emergency Use of Treatment for 

Uncontrolled Hemorrhage During an 

Emergency Involving Agents of Military 

Combat pursuant to section 564 of the 

Federal Food, Drug & Cosmetic (FD&C) 

Act. On July 9, 2018, the Secretary 

declared that circumstances exist 

justifying the authorization of 

emergency use of freeze dried plasma 

(FDP) for the treatment of hemorrhage or 

coagulopathy during an emergency 

involving agents of military combat 

(e.g., firearms, projectiles, and explosive 

devices) when plasma is not available 

for use or when the use of plasma is not 

practical, pursuant to section 564 of the 

FD&C Act, subject to the terms of any 

authorization issued under that section. 

This notice is correcting the July 16, 

2018 notice to correctly state the 

Secretary’s declaration. 

FOR FURTHER INFORMATION CONTACT: 

Robert P. Kadlec, MD, MTM&H, MS, 

Assistant Secretary for Preparedness 

and Response, Office of the Secretary, 

Department of Health and Human 

Services, 200 Independence Avenue 

SW, Washington, DC 20201, Telephone 

(202) 205–2882 (this is not a toll free 

number). 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of July 16, 2018 (83 FR 

32884) appearing on page 32884 in FR 

Doc. 2018–15152 the following 

corrections are made: 

1. Title, change the title of the notice 

to ‘‘Declaration Regarding Emergency 

Use of Treatment for Hemorrhage or 

Coagulopathy During an Emergency 

Involving Agents of Military Combat.’’ 

2. Summary section, change the 

second paragraph to: ’’ On the basis of 

this determination, on July 9, 2018, the 

Secretary declared that circumstances 

exist justifying the authorization of 

emergency use of freeze dried plasma 

(FDP) for the treatment of hemorrhage or 

coagulopathy during an emergency 

involving agents of military combat 

(e.g., firearms, projectiles, and explosive 

devices) when plasma is not available 

for use or when the use of plasma is not 

practical, pursuant to section 564 of the 

FD&C Act, subject to the terms of any 

authorization issued under that 

section.’’ 

3. SUPPLEMENTARY INFORMATION

section, subpart I, Background, second 

paragraph second sentence, delete 

‘‘French’’ before ‘‘FDP.’’ 

4. SUPPLEMENTARY INFORMATION

section, subpart III, Determination of the 

Secretary of Health and Human 

Services, change paragraph 1 to: ‘‘On 

July 9, 2018, on the basis of the Deputy 

Secretary of Defense’s determination 

that there is a military emergency or 

significant potential for a military 

emergency involving a heightened risk 

to U.S. military forces of an attack with 

an agent or agents that may cause, or are 

otherwise associated with an 

imminently life-threatening and specific 

risk to those forces, I declared that 

circumstances exist justifying the 

authorization of emergency use of FDP 

for the treatment of hemorrhage or 

coagulopathy during an emergency 

involving agents of military combat 

(e.g., firearms, projectiles, and explosive 

devices) when plasma is not available 

for use or when the use of plasma is not 

practical, pursuant to section 564 of the 

FD&C Act, subject to the terms of any 

authorization issued under that 

section.’’ 


daltland on DSKBBV9HB2PROD with NOTICES
36942 Federal Register / Vol. 83, No. 147 / Tuesday, July 31, 2018 / Notices 

Dated: July 25, 2018. 

Ann Agnew, 

Executive Secretary to the Department, U.S. 

Department of Health and Human Services. 

[FR Doc. 2018–16331 Filed 7–30–18; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Aging. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

will be closed to the public in 

accordance with the provisions set forth 

in sections 552b(c)(4) and 552b(c)(6), 

Title 5 U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Advisory 

Council on Aging. 

Date: September 13–14, 2018. 

Closed: September 13, 2018, 3:00 p.m. to 

5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, C Wing 6th Floor Conference 

Room 10, 9000 Rockville Pike, Bethesda, MD 

20892. 

Open: September 14, 2018, 8:00 a.m. to 

12:45 p.m. 

Agenda: Call to order and report from the 

Director; Discussion of future meeting dates; 

Consideration of minutes of last meeting; 

Reports from Task Force on Minority Aging 

Research, Working Group on Program; 

Council Speaker; Program Highlights. 

Place: National Institutes of Health, 

Building 31, C Wing 6th Floor Conference 

Room 10, 9000 Rockville Pike, Bethesda, MD 

20892. 

Contact Person: Robin Barr, Director, 

National Institute on Aging, Office of 

Extramural Activities, Gateway Building, 

7201 Wisconsin Avenue, Bethesda, MD 

20814, (301) 496–9322, barrr@nia.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. Information is also available on the 

Institute’s/Center’s home 

page:www.nia.nih.gov/about/naca, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: July 25, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–16294 Filed 7–30–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group Acquired Immunodeficiency 

Syndrome Research Review Committee. 

Date: August 30–31, 2018. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: San Diego Marriott Mission Valley, 

8757 Rio Diego Drive, San Diego, CA 92108. 

Contact Person: Robert C. Unfer, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

Room 3F40A, National Institutes of Health, 

NIAID, 5601 Fishers Lane, MSC 9834, 

Bethesda, MD 20892–9834, (240) 669–5035, 

robert.unfer@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: July 25, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–16296 Filed 7–30–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Quantitative Imaging Tools and Methods for 

Cancer Therapy Response Assessment (UG3/ 

UH3 & U01). 

Date: September 7, 2018. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W640, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Saejeong J. Kim, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W640, Bethesda, MD 

20892–9750, 240–276–5179, saejeong.kim@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Program Project II. 

Date: September 20–21, 2018. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

North Bethesda, MD 20852. 

Contact Person: Anita T. Tandle, Ph.D., 

Scientific Review Officer, Research Program 


daltland on DSKBBV9HB2PROD with NOTICES